InsuletPODD
About: Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Employees: 3,900
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
176% more first-time investments, than exits
New positions opened: 138 | Existing positions closed: 50
20% more capital invested
Capital invested by funds: $18.4B [Q1] → $21.9B (+$3.6B) [Q2]
11% more repeat investments, than reductions
Existing positions increased: 290 | Existing positions reduced: 261
10% more funds holding
Funds holding: 706 [Q1] → 775 (+69) [Q2]
0.01% less ownership
Funds ownership: 99.32% [Q1] → 99.31% (-0.01%) [Q2]
20% less funds holding in top 10
Funds holding in top 10: 5 [Q1] → 4 (-1) [Q2]
55% less call options, than puts
Call options by funds: $67.4M | Put options by funds: $150M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Barclays Matt Miksic | 9%downside $300 | Equal-Weight Maintained | 21 Aug 2025 |
Canaccord Genuity William Plovanic | 7%upside $353 | Buy Maintained | 8 Aug 2025 |
RBC Capital Shagun Singh | 6%upside $350 | Outperform Maintained | 8 Aug 2025 |
Wells Fargo Lawrence Biegelsen | 6%upside $350 | Overweight Maintained | 8 Aug 2025 |
Truist Securities Richard Newitter | 11%upside $365 | Buy Initiated | 16 Jun 2025 |
Financial journalist opinion
Based on 23 articles about PODD published over the past 30 days
